Maria Sklodowska Curie Children's Hospital Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4
Founded: Bucharest Romania (1992)

Organization Overview

First Clinical Trial
1997
NCT00003771
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Maria Sklodowska-Curie Institute - Oncology Center | Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice | Maria Sklodowska-Curie Memorial Cancer Center, Institute of Oncology | Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, POLAND | M.Sklodowska-Curie Memorial, Dep of Lung and Thoracic Tumours, Warsaw | The Maria Sklodowska-Curie Memorial Cancer Centre & Institute of Oncology | The Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 3)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Fibrosarcoma (Phase 2)

Gastrointestinal Hemorrhage (Phase 4)

Gastrointestinal Stromal Tumors (Phase 2)

Gaucher Disease (Phase 2)

Hemorrhage (Phase 4)

Histiocytic Sarcoma (Phase 2)

Histiocytoma, Malignant Fibrous (Phase 2)

Hodgkin Disease (Phase 3)

Leiomyosarcoma (Phase 2)

Liposarcoma (Phase 2)

Liposarcoma, Myxoid (Phase 2)

Lung Neoplasms (Phase 2)

Lymphangiosarcoma (Phase 2)

Lymphoma (Phase 3)

Lymphoma, Non-Hodgkin (Phase 3)

Melanoma (Phase 2)

Multiple Myeloma (Phase 3)

Myosarcoma (Phase 2)

Neoplasms, Plasma Cell (Phase 3)

Nerve Sheath Neoplasms (Phase 2)

Neuroendocrine Tumors (Phase 2)

Neurofibrosarcoma (Phase 2)

Plasmacytoma (Phase 2)

Proctitis (Phase 4)

Rhabdomyosarcoma (Phase 2)

Sarcoma (Phase 2)

Sarcoma, Synovial (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 18
  • # of Trial APIs: 24